AGRX News and Press, Agile Therapeutics Inc. From 03/30/22

Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q4 2021 Earnings Call Mar 30, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q4 2021 Earnings Call Transcript

Agile Therapeutics, Inc. (AGRX) Q4 2021 Earnings Conference Call March 30, 2022 4:30 P.M. ET Company Participants Matt Riley - Head of Investors Relations Dennis Reilly - Chief Financial Officer Al Altomari - Chairman and Chief Executive Officer Conference Call Participants Leland Gershell - ...

Agile Therapeutics press release (NASDAQ:AGRX): Q4 GAAP EPS of -$0.20. Revenue of $1.51M (+101.3% Y/Y). "We ended 2021 with double digit growth in demand quarter over quarter and expect to see that continue in the first quarter of 2022. We are also excited to launch our first CTV commercial i...

Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected to launch in April 2022 and Contribute to Further Demand Growth Company Advances Bus...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, investor! It’s time to go over the biggest pre-market stock movers in our breakdown for Wednesday! Source: Shutterstock Most of the stock movement this morning comes from earnings reports but ...

AESE, AGRX, BEEM, EDAP, GNLN, ISUN, IZEA, KBNT, KMPH, NDRA, OEG, PATH, PHR, RKDA, STON, OTCQX:TLLTF, USWS, VNET For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

Agile Therapeutics (NASDAQ:AGRX) is scheduled to announce Q4 earnings results on Wednesday, March 30th, after market close. The consensus EPS Estimate is -$0.15 (+25.0% Y/Y) and the consensus Revenue Estimate is $1.51M (+101.3% Y/Y). For further details see: Agile Therapeutics Q4 Earnin...

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institut...

Agile Therapeutics (NASDAQ:AGRX) is down ~6% pre-market after announcing a $4.85M equity offering. The women's healthcare company entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferr...

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor...